Clinical Cases in Pharmacology Clinical Cases  ·  Endocrinology, Diabetes and Metabolism III  ·  Pituitary  ·  Oral Paltusotine vs. Injectable SSA
Endocrinology, Diabetes and Metabolism III, Case EndoPituitary-0002 — Pituitary

Trading the Injection for a Pill: Switching Acromegaly Control to Oral Paltusotine

A single patient, biochemically controlled for three years on monthly injectable octreotide, now asking about the newly approved oral alternative. The disagreement isn't about whether paltusotine works — it's about whether "already controlled" is a reason to leave well enough alone.

Abbreviations, terms, and other agents mentioned in this case IGF-1 — insulin-like growth factor 1  ·  GH — growth hormone  ·  SST2 — somatostatin receptor type 2  ·  ULN — upper limit of normal  ·  LAR — long-acting release
Presentation

R.P., a 58-year-old woman, is a courtroom stenographer who has spent three decades transcribing testimony at a keyboard, work that depends on hands that don't ache by the end of a docket day — a small, practical detail that turns out to matter more to this visit than her actual lab values. Acromegaly was diagnosed nine years ago after a routine dental impression stopped fitting and a subsequent workup found a GH-secreting microadenoma; surgery achieved only partial biochemical control, and she has been on monthly injectable octreotide LAR for the past three years, with her IGF-1 normal at every check since dose optimization. She describes the injections themselves as tolerable but logistically corrosive in a specific way: the clinic visit has to be scheduled around court calendars that are set months in advance and change without warning, and twice in the past year she has arrived for her injection only to be turned back because the calendar shifted underneath her.

She raises paltusotine, the oral nonpeptide somatostatin receptor type 2 agonist approved in September 2025, specifically because she read that its own pivotal trial, PATHFNDR-1, enrolled patients exactly like her — biochemically controlled on an injectable somatostatin analog and switched to the oral drug rather than started on it fresh. In that trial, 83% of switched patients maintained IGF-1 at or below the upper limit of normal on paltusotine, against 4% of patients switched to placebo, a result specific to maintaining control already achieved rather than establishing it from an elevated baseline. That distinction is the one worth being precise about: her question isn't whether paltusotine controls acromegaly in general, it's whether a drug proven to hold a patient where octreotide already put her is a reasonable trade for a mechanism she's already responding to, once daily oral dosing replaces a once-monthly injection she has to fight her own court calendar to keep.

R.P. · 58 3 years controlled
History
Acromegaly, microadenoma, partial surgical control 9 years ago
Current regimen
Octreotide LAR 20mg monthly, dose-stable 2 years
IGF-1, most recent
0.9x ULN — normal, consistent for 3 years
Adherence history
2 missed/rescheduled injections in the past year (court calendar conflicts)
Gallbladder
No stones on last ultrasound; asymptomatic
Fasting glucose
94 mg/dL — normal
Cardiac
No valvular disease, EF normal

Controlled on the injection — is that a reason to stay, or to switch anyway

Endocrinologist Opening

I'd support the switch, and not reluctantly. PATHFNDR-1 is the specific trial that answers her actual question — it enrolled patients switched off injectable SSAs who were already controlled, not patients starting from elevated IGF-1, and 83% held IGF-1 at or below the upper limit of normal on paltusotine against 4% on placebo. That's a maintenance-of-control result, which is exactly her situation.

Her adherence problem is real and specific to her job, not a vague preference — two missed injections in a year because a court calendar moved isn't a minor inconvenience, it's a structural gap in her actual control, even though her labs haven't shown it yet.

Clinical Pharmacologist Response

I don't disagree with the trial data, but I'd slow down on the framing that this is a low-stakes swap. She's had three consecutive years of normal IGF-1 on a drug and dosing schedule we know works for her specifically — that's not nothing, and switching mechanisms, even within the same receptor family, means re-establishing that track record from scratch under a new drug's own titration.

The trial data doesn't erase that risk, it bounds it — 17% of switched patients in PATHFNDR-1 did not maintain IGF-1 control, and we don't have three years of real-world experience with paltusotine the way we do with octreotide in her specifically.

Endocrinologist Reply

Fair, and I'd build the switch around exactly that number rather than around it disappearing. Paltusotine's own label starts at 40mg and titrates to 60mg over the first weeks based on IGF-1, with a first re-check well inside that window — if she's one of the 17%, we'd know quickly enough to restart octreotide before any real biochemical drift accumulates, not months later.

Regimen selected
Paltusotine
Oral Nonpeptide SST2 Agonist · 40mg daily, titrate to 60mg
PATHFNDR-1's switch population matches her situation directly; removes the injection-scheduling conflict driving her actual adherence risk.
Octreotide LAR — Discontinuing
Somatostatin Analog (Depot Injection) · 3-year proven regimen
Effective and well-tolerated, but the monthly clinic-visit requirement is the specific friction the switch is meant to resolve.
IGF-1 Recheck at 6 and 12 Weeks
Monitoring Plan, Not a Drug · Scheduled explicitly
Built around the 17% non-maintenance rate from PATHFNDR-1 — an early, explicit checkpoint rather than waiting for her usual annual interval.
Where this was left

Agreed: switch to oral paltusotine, starting at 40mg daily with titration to 60mg guided by IGF-1, with the first recheck moved up to 6 weeks and a second at 12 weeks rather than her usual longer interval — an explicit safety net built around the trial's own non-maintenance rate, not an assumption that three years of control transfers automatically.

Both physicians left aligned on the plan itself; the earlier disagreement was about how much weight her three-year track record deserved against a newer drug's shorter one, not about the switch's basic soundness once PATHFNDR-1's own switch-population data was on the table.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →